A multiple-dose BE study with clinical endpoint comparing Paliperidone Palmitate Prolonged Release suspension for injection 100 mg of Qilu Pharmaceuticals Co., Ltd with Xeplion Prolonged Release suspension for Injection 100 mg of Janssen-Cilag International NV in subjects with schizophrenia.

Category Primary study
Registry of TrialsClinical Trials Registry - India
Year 2024
This article has no abstract
Epistemonikos ID: 2a0980a4eeecde7abb6f0457ec6809b08acc783b
First added on: Apr 09, 2025